RayzeBio Secures $4.1B in Funding, Igniting a New Era of Radiopharmaceutical Innovation with Bristol Myers Squibb

RayzeBio Inc. is thrilled to announce a groundbreaking funding milestone with a total of $4,099,999,999 raised, marking a transformative moment in our journey as we unite with Bristol Myers Squibb. This remarkable infusion of capital not only fuels our vision for delivering breakthrough therapies but also significantly enhances our differentiated radiopharmaceutical platform. As part of the Bristol Myers Squibb family, RayzeBio is poised to leverage this substantial investment to accelerate cutting-edge research and development, catalyze innovative clinical trials, and expand our global reach in addressing some of the most pressing unmet medical needs. Our commitment to harnessing the power of radiopharmaceutical technology continues to evolve as we position ourselves at the forefront of this dynamic field, driving advances that have the potential to reshape patient care and treatment outcomes around the world. The funding will empower us to invest in state-of-the-art facilities, foster interdisciplinary collaborations, and support a robust pipeline of therapies designed to make a real difference in the lives of patients. As we build on our established track record of scientific excellence and strategic partnerships, this capital injection underscores our dedication to innovation and serves as a testament to the confidence our investors have in our vision for the future of medicine. We invite you to follow our ongoing progress and learn more about our breakthrough efforts via Bristol Myers Squibb’s channels and our dedicated online resource at www.bms.com, as we embark together on an exciting chapter poised to redefine the landscape of radiopharmaceutical therapy and patient care worldwide.